Ingolf J. B.
- Country
- Germany
- Department
- Gynäkologie & Geburtshilfe
Research Overview
- CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
- A Phase II randomized, open label non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy
- Phase III Randomized Double-Blind Placebo-Controlled Trial of Letrozole Maintenance Therapy in Epithelial Ovarian Cancer Post-Surgery and Chemotherapy
Data & Insights
Has run more than one trial at 63 of 206 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in studying therapeutic approaches for advanced breast cancer, with particular focus on HER2-negative, hormone receptor positive (HER2neg/HR+) disease types.
- Advanced Stage Treatment
- First-line Therapeutic Strategies
- Hormone Receptor Positive Disease
Research activities concentrate on evaluating treatment efficacy in breast cancer management.
Treatment Response Analysis
Expertise in analyzing spatial and temporal patterns of treatment response, with emphasis on understanding therapeutic efficacy and resistance mechanisms in breast cancer patients.
- Treatment Resistance Patterns
- Response Monitoring
- Molecular Pattern Analysis
Focus includes comprehensive evaluation of treatment outcomes and survival metrics.
Clinical Outcomes
Specialized in assessing key clinical endpoints including progression-free survival and overall survival in advanced breast cancer treatment.
- Survival Rate Analysis
- Disease Progression Monitoring
- Long-term Outcome Assessment
Research encompasses evaluation of treatment effectiveness through survival metrics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.